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Abstract
Background: Motor neurone disease (MND) practice guidelines suggest developing interventions that will promote hope,
meaning, and dignity to alleviate psychological distress, but very little research has been done. This study begins to address
this need by exploring the use of dignity therapy with people with MND. Dignity therapy is a brief psychotherapy that
promotes hope, meaning and dignity, and enhances the end of life for people with advanced cancer. The aims of this study
are to assess the feasibility, acceptability, and potential effectiveness of dignity therapy for people with MND.
Methods/design: This cross-sectional feasibility study used a one-group pre-test post-test design with 29 people diagnosed
with MND. Study participants completed the following self-report questionnaires: Herth Hope Index, FACIT-sp, Patient
Dignity Inventory, ALS Assessment Questionnaire, ALS Cognitive Behavioural Screen, and a demographic and health history
questionnaire. Acceptability was measured with a 25-item feedback questionnaire. Feasibility was assessed by examining
the length of time taken to complete dignity therapy and how symptoms common in MND affected the intervention.
Generalised linear mixed models and reliable change scores were used to analyse the data.
Results: There were no significant pre-test post-test changes for hopefulness, spirituality or dignity on the group level, but
there were changes in hopefulness on the individual level. The results of the feedback questionnaire indicates dignity
therapy is highly acceptable to people with MND, who report benefits similar to those in the international randomised
controlled trial on dignity therapy, a population who primarily had end-stage cancer. Benefits include better family
relationships, improved sense of self and greater acceptance. Dignity therapy with people with MND is feasible if the
therapist can overcome time and communication difficulties.
Conclusions: Dignity therapy for people with MND is feasible and acceptable. Further research is warranted to explore its
ability to diminish distress.
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Introduction
Motor neurone disease (MND), also known as amyotrophic
lateral sclerosis, is an uncommon neurodegenerative disease that is
progressive and always fatal. There is no cure and few options exist
for treatment. While a few die within six months, others live ten
years or more. On average, people live two to three years after
diagnosis before eventually succumbing to paralysis and death,
most often from respiratory failure [1,2].
Despite the considerable physical and emotional suffering
involved, there is little focus on addressing the psychological
needs of people with MND. Quality of life is generally high [3–5],
but people with MND often experience significant psychological
distress including anxiety and hopelessness [6]. Psychological
distress in MND is associated with decreased quality of life and
decreased survival rates [7,8]. Hopelessness is correlated with
interest in hastened death [3,9,10]. Among those with terminal
diagnoses, people with MND report the highest levels of interest in
hastened death [11] and they also have the greatest risk of suicide
[12]. These effects are mitigated in people who report higher levels
of spirituality and sense of meaning [13,14]. Such findings have led
to calls for psychological interventions to bolster hopefulness,
spirituality, and meaning in people with MND [1,15]; however,
intervention studies are lacking.
One promising intervention is dignity therapy; a brief psycho-
therapeutic intervention based on an empirical understanding of
dignity at the end of life [16]. Dignity therapy offers people facing
death the opportunity to create a document about their life [17].
In a recorded life reflection interview, a person with terminal
disease is afforded the opportunity to discuss significant memories,
meaningful events and important accomplishments, as well as
leave messages for loved ones. In previous studies, dignity therapy
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has been shown to alleviate existential distress in a palliative care
population where most people had malignant conditions [18,19].
With a key aim to bolster hope and meaning, dignity therapy has
the potential to alleviate psychological distress in people with
MND [15]. However, because most of the people in previous
dignity therapy research had terminal cancer, the findings of its
effectiveness are not transferable to people with MND. Diagnosis,
ability to communicate, cognitive acuity, stage of illness, baseline
levels of distress and demographic features are factors that
differentiate people with MND from people with end-stage cancer.
Finally, delivery of dignity therapy to people with MND may
require modification, for example, to be performed at an earlier
time or via assisted communication methods.
Aims and objectives
The aim of this study was to assess the feasibility, acceptability,
and potential effectiveness of dignity therapy to enhance the end of
life experience for people with MND. The specific objectives were
to determine whether:
a) dignity therapy increases hope, meaning, and dignity in
people with MND;
b) dignity therapy is acceptable to people with MND; and
c) it is feasible to provide dignity therapy to people with MND.
Methods
Study design
This cross-sectional study utilized a one-group pre-test-post-test
design. A control group was not utilized due to 1) the small MND
population, 2) access issues to people with MND, 3) ethical
concerns over making a potentially useful intervention unavailable
to a control group, and 4) the need to test the feasibility of dignity
therapy with people with MND [20,21]. Further details can be
found in our protocol [22].
Ethical approval
This study was approved by the Curtin University Human
Research Ethics Committee (19/2011).
Setting
Participants were primarily enrolled as a result of outreach from
the Motor Neurone Disease Association of Western Australia
(MNDAWA). MNDAWA sent recruitment letters to people who
had been diagnosed with MND and referred to their services by a
general practitioner or neurologist. In the last six months of the
study, we used social networking, a press release, and information
on the university web site to assist in reaching the recruitment goal.
One participant in Queensland participated via video-conferenc-
ing. Twenty-two participants reported living in an urban/
metropolitan area and seven in rural areas. Twenty-seven
participants were living at home at the time of the intervention,
one in an aged-care facility and one a hospital.
Participants
Individuals diagnosed with MND, over 18 years old, who could
communicate in English and provide informed consent (based on
the ALS-Cognitive Behavioural Screen (ALS-CBS) [23] where a
cut-off score of 10 was used or the Blessed Orientation Memory
Concentration (BOMC) test [24] where a cut-off score of 9 was
used) were eligible for the study. Participants were provided with
information sheets and written consent was obtained. Enrolment
occurred between June 2011 and July 2013. People were excluded
if they were too ill to complete the requirements of the protocol.
There were no selection criteria based on distress levels, disease
stage or proximity to death.
The intervention
The intervention was administered by a researcher trained in
dignity therapy by Harvey Max Chochinov who developed the
therapy [18,19]. The therapy interviews were audio-recorded and
transcribed verbatim by a transcriptionist. The researcher shaped
the transcribed interviews using the prescribed editing process [17]
and then returned to edit and complete the transcripts with the
participants. The document was read aloud to each participant at
the conclusion of the intervention. To mitigate response bias, post-
testing took place via mail or through a visit from a second
researcher. The researcher engaged in regular supervision sessions
from Prof. Chochinov. To optimize adherence to the dignity
therapy protocol, three recordings, transcripts, and completed
documents (10%) were reviewed by three experienced researchers
(two trained in dignity therapy) and deemed to be adherent.
Measures and Outcomes
Effectiveness. Outcome data to measure potential effective-
ness were collected from participants at baseline and one week
after completion of dignity therapy. The primary outcome
measure was the participant’s sense of hopefulness assessed
with the Herth Hope Index [25,26], a reliable (a=0.97) validated
instrument developed for use with the terminally ill, with a score
ranging from 12–48 and where higher scores indicate more
hopefulness. Secondary outcomes were: 1) Dignity, measured by
the Patient Dignity Inventory (PDI) [27]. The PDI has a scale of
25–125 (higher scores indicate greater distress). It is a reliable
(a=0.93) validated measure which evolved directly from the
empirical studies into dignity concerns in the terminally ill. [27] 2)
Spiritual well-being, measured by the Spiritual Well-Being
subscale of the Functional Assessment of Chronic Illness Therapy
scale (FACIT-sp-12) [28]. The FACIT-sp-12 has a scale of 0–48
with higher scores indicating greater spiritual wellbeing, and it is a
reliable (a=0.87) and valid measure [28].
Acceptability. The Participant Feedback Questionnaire used
in the international randomised controlled trial of dignity therapy
(IRCT) [19] was modified by adding three items on hopefulness
and family support, and was used to collect the participants’
experiences and opinions of the intervention. The questionnaire
contained 25 questions answered with a 5-point Likert scale and
space for brief explanation.
Feasibility. Data were collected about the time taken to
conduct the therapy sessions, any special accommodations made
in the delivery of the intervention, deviations from the dignity
therapy protocol, reasons for non-completion, and reasons for
attrition.
Demographic and health status. Disease specific health-
related quality of life was measured with the Amyotrophic Lateral
Sclerosis Assessment Questionnaire-5 (ALSAQ-5) where scores
range from 0–20 (higher scores indicating more impairment) [29],
and cognitive behavioural functioning was assessed with the ALS –
CBS [23]. Level of impairment of the person with MND and
change in physical function over time was collected from the
family carer using the Amyotrophic Lateral Sclerosis Functional
Rating Scale-R (ALS-FRS) where scores range from 0–48 (lower
scores indicating more impairment) [30,31]. Demographic data on
age, gender, education level, marital status, and health history
were also collected.
Dignity Therapy for People with MND
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Analysis
Data were analysed with generalised linear mixed models
(GLMM) as implemented through SPSS’s (Version 20) GENLIN-
MIXED procedure. Model parameters were estimated with robust
standard errors in order to accommodate potential violations of
the model assumptions. Participant was treated as a random effect
and Time (pre-test, post-test) was treated as a fixed effect. Age,
gender, time since diagnosis, marital status, level of education, and
number of days from pre-test to post-test were also treated as fixed
effects and analysed individually as potential moderators of the
intervention effect. In order to optimise the likelihood of
convergence, a separate GLMM analysis was run for each of the
three outcome measures. The GLMM maximum likelihood
procedure is a full information estimation procedure that uses all
the data present at each assessment point. All of the pre-test data
and all of the post-test data are incorporated into the analysis,
which reduces sampling bias associated with participant attrition.
GPower (Version 3.1) indicated that 29 participants would be
sufficient to capture ‘moderate to large’ (f= .28) pre-post changes
on the outcome variables. A reliable change (RC) score for each
participant [32] was computed to investigate the presence of
reliable pre-post change at the individual rather than group level.
The RC score is the degree to which the person changes on the
outcome variable divided by the standard error of difference
between the pre- and post-test scores. When the absolute value of
the RC score is greater than 1.96, (Wise [33] has argued that this
value can be reduced in some situations), it is likely that the post-
test score reflects a real or reliable change. Descriptive statistics were
used to summarize demographic variables and feedback responses.
Results
Response rate
MNDAWA distributed recruitment letters to all 147 members
diagnosed with MND on three occasions between May 2011 and
May 2013. Thirty-five people responded (response rate 24%) and
29 of these people completed the study (completion rate 78%).
Those who did not complete include three people who changed
their mind before entering the study, two who changed their mind
after entering the study, two who died before completion and one
who was excluded due to cognitive impairment. While all 29
completed dignity therapy, one did not complete any post-test
measures due to illness, one completed the feedback questionnaire
but not the outcome measures, and three additional participants
did not complete the PDI fully.
Demographic information
Participants, 20 men and 9 women, ranged from 32 to 81 years
of age with almost half between the ages of 60 and 69. Twenty-
four were married or partnered. Thirteen reached secondary
education; 16 achieved university or postgraduate education. (See
Table 1 for more demographic information on the study
population).
Baseline levels of impairment and distress
The sample group was moderately impaired (ALS-FRS mean
= 32.61, SD =9.76). Scores on the ALSAQ-5 indicate the sample
had moderate health-related quality of life (mean = 9.31, SD
=3.96). The group was hopeful, had low dignity-related distress,
but appeared to be facing some struggles with their spiritual
wellbeing (see Table 2 Pre-test scores). The mean total score for
spiritual wellbeing was 30.7 (SD =10.43) which was lower than in
people with cancer (mean = 38.5, SD=8.1) [28].
Effectiveness
Descriptive statistics for the outcome variables are reported in
Table 2. There were no significant pre-test post-test changes for
hopefulness (F [1,54] = 2.79, p= .101, d= .46), dignity (F [1,54]
= 0.45, p= .504, d= .20), or spirituality (F [1,54] = 0.01, p= .936,
d= .05). Potential moderators of the intervention effect (age,
gender, time since diagnosis, marital status, level of education, and
number of days from pre-test to post-test) were individually
entered in the regression model in order to determine whether
significant pre-test-post-test changes would be observed at certain
values of the moderator. There was no significant Moderator x
Time interactions for any outcomes (all ps ..1).
A reliable change (RC) score for each participant [32]. The
results indicate that some individuals showed an improvement in
hopefulness, while a quarter showed deterioration (see Table 3).
Interestingly, all of the study participants who had an increase in
hopefulness reported they were both religious and spiritual, while
43% of the group whose hopefulness declined reported they were
neither religious nor spiritual. Additionally, 50% of the group with
improved hopefulness had been diagnosed with MND for four
years of more, while 85% of the group that declined had been
diagnosed for two years or less.
Acceptability
The participants found dignity therapy to be satisfactory
(92.8%), helpful to them (89.2%), helpful to their family (85.2%),
and would recommend dignity therapy to others with MND
(84%). They reported the strongest positive improvements in the
dignity-related areas of looking after unfinished business (67.9%),
continuity of self (67.9%) acceptance (64.2%), and role preserva-
tion (60.8%). There were lesser improvements in feeling like a
burden (28.6%), increased will to live (33.3%), lessened sadness or
depression (35.7%), and sense of control (35.7%). Seventy percent
reported they felt closer to the people who meant the most to them
after dignity therapy, and 63% felt dignity therapy would result in
better appreciation in them from their families.
The results of the feedback questionnaire are very similar to the
results of the dignity therapy arm in the IRCT which showed that
dignity therapy outperformed standard care in a palliative care
population where 96% suffered from end-stage cancer [19] (see
Table 4). In both studies, people undergoing dignity therapy
reported the psychotherapy was helpful to them, improved their
quality of life and increased meaning. These findings demonstrate
that people with MND experience similar benefits from dignity
therapy as reported in previous research with people with cancer
[19] (see Table 4).
Feasibility
Dignity therapy for the sample took from three to seven sessions,
consistent with the standard protocol [17,34]. The majority of
participants (69%) finished the therapy in four sessions (mean
= 4.14). Four participants (13.8%) completed in the standard of
two weeks [19]. The time to completion ranged from 7 to 152
days, with about half completing by 25 days (mean = 42, SD=36).
Reasons for extended completion times included (often in
combination) the participants’ speech impairment, travel, hospital
or respite care admissions, family and employment obligations,
and desire for more time to work on the document [35].
Participants’ use of various assisted communication methods
meant that dignity therapy was successfully completed with six
people who, due to MND, had lost the ability to speak. An
additional three people had moderate speech impairment and
these participants had the three longest completion times (87, 134,
Dignity Therapy for People with MND
PLOS ONE | www.plosone.org 3 May 2014 | Volume 9 | Issue 5 | e96888
Table 1. Demographic characteristics of study group.
Gender
Male 20
Female 9
Age
30–39 1
40–49 1
50–59 4
60–69 15
70–79 6
80–89 2
Marital Status
Married 24
Widowed 3
Divorced/separated 1
Never married 1
Residence area
Urban/metropolitan 22
Rural 7
Residence type
Home 27
Hospital 1
Aged-care facility 1
Presently living with
Spouse 23
Alone 4
Other 2
Highest level of education attained
Secondary/high school 13
University/technical 13
Postgraduate 3
Current employment status
None 22
Full-time 2
Part-time 3
On leave 2
Time since diagnosis
Less than one year 8
One to two years 9
Two to three years 4
Three to four years 0
More than four years 8
Time since initial symptoms
Less than one year 2
One to two years 10
Two to three years 5
Three to four years 3
More than four years 9
Prior history of depression (before MND diagnosis)
Yes 6
No 23
Have you been prescribed medication to help you cope?
Dignity Therapy for People with MND
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and 152 days). One participant with moderate speech impairment
completed the intervention using videoconferencing and email.
Discussion
This is the first study to explore the feasibility of dignity therapy
with people with MND and, to our knowledge, the first study of a
targeted psychotherapeutic intervention for this population. We
expected to detect measureable post-intervention increases in
hope, dignity and spirituality at the group level but this did not
occur. This may be due to a number of reasons, including the
difficulties with demonstrating psychosocial change at the end of
life with self-report measures [36], the result of evidence which
suggests the benefits of psychosocial interventions at the end of life
can most readily be shown in patients who have elevated levels of
distress [37], and/or that the outcome measures chosen were not
sensitive to the impacts that occurred. Very small pre-post effects
were present for dignity and spirituality, and the effect for
hopelessness was small to moderate. However, without a control
group, we were unable to ascertain whether the intervention had a
prevention effect against expected declines in hope, dignity, and
spirituality over time as a person with MND deteriorates and
approaches death. At the individual level, tentative findings are
that dignity therapy may be effective at increasing hopefulness in
people who are more spiritual and also in some with advanced
disease, as reported in previous research [38].
Nonetheless, the positive results on the feedback survey indicate
most people with MND believe dignity therapy to be beneficial.
The intervention was found to be overwhelmingly positive.
Feedback indicated dignity therapy helped enhance the end of
life by supporting the unique identity of the person, helping with
acceptance, allaying aftermath concerns, finding meaning and
purpose, and improving family relationships which mirrors the
previous findings of the pilot study and international randomised
controlled trial of dignity therapy performed with people with end-
stage cancer [18,19]. Moreoever, people with MND believe
dignity therapy will be of help to their family members after death
indicating a potential benefit to family members during bereave-
ment as found in other studies [39,40]
Feasibility
Dignity therapy with people with MND is feasible if the
therapist can overcome time and communication difficulties, as it
takes longer to administer with people who have MND than those
with cancer. Therapist time was increased in order to travel to
participants in their homes to deliver the intervention (previously
completed in palliative care settings [19,34]) and was compounded
for participants in rural areas. Ninety-three percent of participants
were in the community rather than an in inpatient or care facility.
As such, we were less in control of the schedule. Additionally, for
people with speech impairment, dignity therapy was prohibitively
difficult and time consuming to perform. Adapted methods appear
Table 1. Cont.
Gender
Anti-depressant 7
Anti-anxiety 2
Sleeping medication 1
Anti-anxiety & sleeping medication 1
No 18
Do you consider yourself to be a religious person?
Yes 8
Somewhat 10
No 11
Do you consider yourself to be a spiritual person?
Yes 10
Somewhat 14
No 5
Cognitive screening scores
No impairment 19
Suspected mild to moderate impairment 10
doi:10.1371/journal.pone.0096888.t001
Table 2. Mean Pre-test Post-Test Scores on Measures for Hopefulness, Dignity, and Spirituality.
Outcome Pre-test N Post-test N
Hopefulness (HHI) 38.76 (5.10) 29 36.61 (6.80) 27
Dignity (PDI) 48.59 (15.45) 29 47.59 (12.91) 24
Spirituality (FACIT-sp-12) 30.72 (10.43) 29 30.92 (9.88) 27
doi:10.1371/journal.pone.0096888.t002
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to present viable solutions to these issues, such as some of the
therapy being conducted via email or utilizing videoconferencing.
Unique aspects common to MND, including speech impairment
and mild to moderate cognitive impairment, did not detract from
the benefits of the therapy. These results indicate that dignity
therapy is feasible and acceptable, and it offers potential benefits
for people with MND.
Strengths and limitations
The strengths of this feasibility study were the high response
rate, high completion rate, a group representative of people with
MND in demographic and health status characteristics, the use of
MND-specific cognitive and health status measures, and the
measure used to assess acceptability being nearly identical to the
one used in the dignity therapy international randomised
controlled trial, which allows for comparison. The limitations
include inadequate power to discover small effects, mild to
moderate levels of distress at baseline, the lack of a control group,
and the use of outcome measures not developed or validated for
use with people who have MND. The study group may not be
representative of the MND population as a whole as those who
selected to participate may have been more likely to think dignity
therapy would be beneficial.
Table 3. Percentage (Number) of Participants Showing Reliable Improvement, Deterioration, and No Change for Hopefulness,
Dignity, and Spirituality.
Outcome Improved Deteriorated No change N
Hopefulness (HHI) 14.8 (4) 25.9 (7) 59.3 (16) 27
Dignity (PDI) 0 0 100 (24) 24
Spirituality (FACIT-sp-12) 0 0 100 (27) 27
doi:10.1371/journal.pone.0096888.t003
Table 4. Results of the Participant Feedback Questionnaire Compared to Dignity Therapy and Standard Care in the IRCT [19].
People w/MND
(n =28)
Dignity therapy IRCT
(n=108)
Standard palliative care
IRCT (n=111)
DT has been helpful to me 4.18 (0.72) 4.23 (0.64) 3.50 (1.01)
DT has been as helpful as any other aspect of my health care 3.50 (0.88) 3.63 (1.04) 3.27 (1.04)
DT has improved my quality of life 3.39 (0.79) 3.54 (0.95) 2.96 (0.96)
DT has given me a sense of looking after unfinished business 3.68 (0.61) 3.35 (1.01) 2.86 (1.60)
DT has improved my spiritual wellbeing 3.36 (0.68) 3.27 (1.09) 3.00 (1.11)
DT has lessened my sadness or depression 3.04 (0.96) 3.11 (1.02) 2.57 (0.92)
DT has lessened my sense of feeling a burden to others 2.96 (0.92) 2.81 (0.98) 2.58 (0.95)
DT has made me feel more worthwhile or valued 3.50 (0.79) 3.38 (0.93) 3.35 (1.00)
DT has made me feel like I am still me 3.71 (0.85) 3.81 (0.85) 3.59 (0.92)
DT has given me a greater sense of having control over my life 3.18 (0.77) 3.02 (1.02) 3.16 (1.00)
DT has helped me to accept the way things are 3.54 (0.92) 3.39 (1.062) 3.31 (1.01)
DT has made me feel more respected and understood by others 3.33 (0.98) 3.16 (0.90) 3.04 (0.98)
DT has made me feel that I am still able to carry out important
tasks or fill an important role
3.61 (0.99) 3.62 (0.97) 3.48 (1.00)
I have found DT to be satisfactory 4.21 (0.69) 4.26 (0.63) 3.80 (0.74)
DT has made me feel that my life currently is more meaningful 3.54 (0.69) 3.55 (1.05) 3.19 (1.70)
DT has given me a heightened sense of purpose 3.32 (0.82) 3.49 (1.04) 3.20 (0.98)
DT has given me a heightened sense of dignity 3.36 (0.87) 3.52 (1.04) 3.09 (1.02)
DT has made me feel more hopeful 3.00 (0.86) N/R N/R
DT has lessened my suffering 3.25 (0.75) 2.86 (1.04) 2.70 (1.02)
DT has increased my will to live 2.96 (0.98) 2.94 (1.11) 2.76 (1.04)
DT has helped me feel closer to people who mean the most to
me
3.63 (0.97) N/R N/R
DT has or will be of help to my family 4.00 (0.78) 3.93 (0.80) 3.20 (1.00)
DT could change the way my family sees or appreciates me 3.48 (1.05) 3.58 (1.01) 2.85 (1.00)
I would recommend DT to other patients and family dealing
with motor neurone disease
4.04 (0.98) N/R N/R
Note: Data are mean (SD). Score 1 is strongly disagree, 2 disagree, 3 neither agree nor disagree, 4 agree, 5 strongly agree. N/R = not reported.
doi:10.1371/journal.pone.0096888.t004
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Implications for future research
This feasibility study sets the stage for a phase II randomised
controlled trial. Potential effectiveness should be further explored
through research with people with MND with elevated distress.
Research into conducting the intervention via email and through
videoconferencing is also indicated. There has been one small
study with eight participants showing dignity therapy can be
delivered using videoconferencing [41] but a larger study is
warranted. Future studies should include hope as an outcome as
well as explore the possible relationship between a person’s
spirituality and changes to hopefulness through dignity therapy.
Conclusions
Dignity therapy for people with MND is feasible and the unique
features of MND, including speech impairment and mild to
moderate cognitive impairment can be managed, but the
intervention is likely to take a greater length of time to complete
compared to previous studies, especially with those individuals
experiencing speech impairment who do not utilize assisted
communication. Dignity therapy is acceptable to people with
MND, who report numerous benefits. Further research is
warranted to explore its ability to diminish distress.
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